Launched in 2018, the platform offers a blended learning approach to complement in-person and on-the-job training. A recent platform update in 2024 introduced new features, security enhancements, and a modernized interface.
Globally, users have completed over 435,000 courses in Hemostasis, Acute Care, and Autoimmunity, with the highest enrollments in operator training for the ACL TOP Family 50 Series and GEM Premier 5000, as well as educational courses on Hemophilia, Anticoagulation Monitoring, Preanalytical Issues, and Antiphospholipid Syndrome.
But what about EEMEA? Well, as you know, our diverse and multicultural region is continuously growing, and as of November 2024 has exceeded 3,200 users:

KSA remains the undisputed leader among the top performers, accounting for approximately 40% of our users. Poland and Romania continue to hold their strong positions in second and third place, respectively, with significant contributions in translating content and promoting the platform.

Examining the courses with the highest enrolment in the EEMEA region, the following trainings stand out as the most popular:

In terms of recently released trainings, it is definitely worth mentioning:
HEMOSTASIS
- Hemostasis Education/Anticoagulant Therapy. DOACs and Cancer: Assessing Drug-Drug Interactions (HEW82).
- Hemostasis Education/Antiphospholipid Syndrome. New Insights in Diagnosis and Treatment of Antiphospholipid Syndrome (HEW81).
- Hemostasis Education/COVID-19. COVID-19 and Thrombosis: An Update (HEW80).
ACUTE CARE
- Acute Care Education/Patient Blood Management. Bleeding Management with Viscoelastic Testing (ACW51).
- Acute Care Education/Patient Blood Management. Patient Blood Management: A Focus on Perioperative Coagulation Management in Cardiac Surgery and Liver Transplantation (ACW50).
- Acute Care Education/Blood Gas/BMP Testing. Challenges in Preanalytical Error Detection: Impact of Hemolysis and Potential Solutions (ACW49).
- Acute Care Education/Blood Gas/BMP Testing. Today's Drive Toward Better Quality Control (ACW48).
AUTOIMMUNITY
- Autoimmune Education/Myositis. The Role of Anti-HMGCR Autoantibodies in Myositis (AIW34).
- Autoimmune Education. The Past, Present and Future of ANA Testing (AIW33).
Featured NEW Courses
- DOACs and Cancer: Assessing Drug-Drug Interactions (HEW82)
This Werfen-sponsored ISTH webinar, featuring Dr. Tristan Groves and Tzu-Fei Wang, highlights the increased risk of VTE in cancer patients, necessitating anticoagulation.
DOACs are becoming popular for treating cancer-associated thrombosis due to their convenience over LMWHs. However, interactions with cancer drugs via CYP3A4 and P-gp pathways limit the use of apixaban to about one-third of patients.
Challenges and Considerations: Predicting interactions can be complex, and switching DOACs can sometimes avoid them. Appropriate routine tests and databases like Lexicomp and University of Liverpool drug interaction checker represent useful tools.
Conclusion: Drug-drug interactions with anticoagulants in cancer patients are common and require careful management. Personalized medicine is crucial for both cancer therapy and anticoagulation.
- The Role of Anti-HMGCR Autoantibodies in Myositis (AIW34)
This Werfen webinar, featuring Dr. Lisa Christopher-Stine, focuses on myositis, a systemic disease primarily causing muscle weakness, and the related discovery of anti-HMGCR antibodies in 2011, where Dr. Lisa Christopher-Stine played a key role.
Case Study: a 58-yr old woman with a history of lipidemia referred to the Johns Hopkins Myositis Center in Baltimore experiencing muscle pain and weakness after taking atorvastatin. This case uncovered a condition where statins trigger an autoimmune response, leading to muscle disease. The disease onset is, on average, 3 yrs after drug exposure, and may persist even after statin discontinuation.
Further in-depth analysis allowed to the identification of anti-HMGCR antibodies in patients with necrotizing myopathy, often linked to statin use. Testing for these antibodies is specific and sensitive, reducing the need for muscle biopsies.
Conclusion: The discovery of anti-HMGCR antibodies has significantly advanced the understanding and management of some types of necrotizing autoimmune myopathies. Personalized treatment and careful monitoring are essential for improving patient outcomes.
Looking forward to leverage more and more on Werfen Academy,
Werfen Academy Team



